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Abstract: Camptothecin (CPT) is a naturally occurring
alkaloid that shows promise in antitumor activity in vitro
against various tumor cell lines. Its potential clinical uses,
however, are hindered by a lack of reaction selectivity and
poor water solubility. Presented herein is a novel polyro-
taxane (PR)-based delivery system that could potentially
lead to a highly effective yet less toxic CPT therapy. The
approach involves the synthesis of the PR–CPT conjugates
via hydrolyzable linkages. To enhance the therapeutic effi-
cacy of CPT, a cell-penetrating peptide, LMWP, is linked
to the conjugate to allow specific, intratumoral delivery of
CPT. To avoid nonselective uptake of the conjugates by
normal tissues following administration, the cell-penetrat-
ing function of LMWP on the conjugates is masked by
heparin binding. This system was designed such that after
accumulation at the tumor via the enhanced permeability
and retention (EPR) effect, protamine can be subsequently
administered to unmask heparin inhibition on LMWP, per-
mitting intracellular uptake of the LMWP–PR–CPT conju-
gates. Once inside the tumor, CPT molecules are detached
from the PR chain by hydrolysis, yielding a sustained con-
centration of CPT within tumor cells. In this paper, we
demonstrated the in vitro feasibility of this delivery system.
The LMWP–PR–CPT conjugates yielded a sevenfold
increase in the overall CPT solubility, as well as a sus-
tained release of CPT over a period of more than 7 days.
Intracellular uptake of these conjugates by A2780 human
ovarian cancer cells and regulation of such uptake by hep-
arin and protamine were tested by MTT assay and confo-
cal/flow cytometric methods, respectively.  2007 Wiley
Periodicals, Inc. J Biomed Mater Res 84A: 238–246, 2008
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INTRODUCTION
Many anticancer drugs that are effective in vitro
may not be effective in vivo because of undesirable
physicochemical behavior (e.g., poor solubility) and/
or toxic side effects. Since all of the intrinsic proper-
ties of a drug are fixed after synthesis, the only
means to overcome such problems and thereby
improve the clinical applicability of the drug is via
the design of an appropriate delivery system. Camp-
tothecin (CPT) represents a typical example of such
antitumor agents. It is a naturally occurring alkaloid
isolated from the Chinese tree Camptotheca acuminata,
with promising antitumor activity against various
leukemia cell lines.1 The intact lactone structure of
CPT forms a noncovalent complex with topoisomer-
ase I and DNA, inhibiting the resealing process of
the broken DNA backbone and thus yielding antitu-
mor effects. However, because of a lack of reaction
selectivity, the use of CPT can cause severe side
effects such as gastrointestinal toxicities. In addition,
CPT is poorly soluble in aqueous media,2 thereby
limiting its effectiveness in clinical applications.
Because of these restrictions, further investigation of
CPT as an anticancer agent was discontinued in the
1970s. More recently, however, several modified
CPT derivatives possessing increased solubility and
reduced toxicity have been developed. Among these
derivatives, irinotecan (CPT-11) and topotecan (TPT)
have indeed already been approved for the treat-
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ment of colorectal and ovarian cancers. Unfortu-
nately, in aqueous solutions the lactone ring of these
CPT derivatives undergoes a rapid, reversible, and
pH-dependent hydrolysis, yielding an open-ring car-
boxylate structure that has far less potent anticancer
effects, and also presents a risk of causing hemor-
rhagic cystitis.3 The quest for a delivery system to
improve the clinical efficacy of CPT thus continues.
During tumor angiogenesis, the nascent capillaries
supplying nutrients to the tumors possess large gaps
in between vascular endothelial cells when com-
pared to healthy tissues. These gaps render the
blood vessels of the tumor permeable to macromole-
cules (>30 kDa), whereas the capillaries in normal
tissues typically do not allow these large molecules
to traverse. Furthermore, the macromolecules tend to
collect and accumulate in the interstitial space of the
tumor due to the lack of a developed lymphatic
drainage system. This phenomenon is known as the
enhanced permeability and retention (EPR) effect,4
and has been widely exploited as a passive means
for tumor targeting with macromolecular drug car-
rier systems.4–6
The use of supramolecular assemblies of biocom-
patible and biodegradable polyrotaxane (PR) as a
drug delivery vehicle has recently drawn great inter-
est.7 The name ‘‘rotaxane’’ comes from the Latin
words for wheel and axle, and thus the term ‘‘polyro-
taxane’’ refers to a molecular assembly in which sev-
eral cyclic molecules (e.g., a-cyclodextrin; a-CD) are
threaded onto a linear polymer (e.g., PEG) chain.
Bulky blocking groups (e.g., tyrosine) are then intro-
duced at the ends, as caps to prevent the PR from
dethreading. Small drug molecules can be linked to
the abundant OH groups on the CD molecules by
hydrolysable (e.g., ester) bonds, thus allowing for a
sustained release of the attached drugs over a pro-
longed period. In addition, the bulky caps can also
be linked with a cleavable bond to permit eventual
dethreading of PR into its constituents of CD and
PEG; both are biocompatible and can be readily
cleared from the body.8,9
Because of the impermeable nature of the cell
membrane, many drugs, particularly large and
hydrophilic agents, cannot internalize tumor cells to
exert their therapeutic effects. In this regard, the
recent discovery of the class of cell-penetrating or
protein transduction domain (PTD) peptides has
produced tremendous interests in drug delivery
research, because it may now be possible to resolve
the issue of poor cellular uptake by many drugs.
Several PTD peptides have been identified, including
TAT from human immunodeficiency virus (HIV-1),10
VP22 from herpes simplex virus,11 ANTP homeotic
transcription factor from Drosophila Antennapedia,12
certain synthetic arginine-rich peptides,13 and the
low molecular weight protamine (LMWP) peptide
developed in our laboratory by enzymatic digestion
from native protamine.14–17 Both in vitro and in vivo
studies have shown that, by covalently linking PTDs
to almost any species, including large proteins (Mw
> 150 kDa) and nanocarriers, these PTDs are able to
ferry the attached species across cell membranes of
all organ types including the brain.10,18 This PTD-
mediated cell entry has been shown to be receptor
independent, and appears to require a surface
adsorption step, likely via binding to the anionic
heparin sulfate molecules on the cell surface, since
PTD-mediated cell uptake was completely inhibited
by the presence of heparin.10,13 This PTD-mediated
cell entry is kinetically far more efficient compared
with existing uptake methods, such as receptor-
mediated endocytosis.17 Yet, the absence of target se-
lectivity in cell entry renders this method an unac-
ceptable practice, due to concerns of drug-associated
toxic side effects.
Proposed herein is a novel PR-based carrier sys-
tem for effective delivery of CPT (Fig. 1). To further
enhance the therapeutic efficacy of CPT and reduce
its toxic effect to the surrounding tissues, a cell-pene-
trating peptide is linked to the PR–CPT conjugate to
allow for tumor-specific, intracellular delivery of
CPT. In order to avoid nonselective uptake of the
conjugates by normal tissues following administra-
tion, the transmembrane function of LMWP on the
conjugates is masked by binding with heparin.
Finally, after accumulation of the conjugates at the
tumor site by EPR-mediated passive targeting, prota-
mine sulfate, a clinical heparin antagonist that binds
to heparin with greater affinity than do LMWP, can
be subsequently administered to unmask LMWP,
thereby permitting a highly effective targeted intra-
cellular uptake of the PR–CPT–LMWP conjugates.
Once inside tumor cells, CPT can detach from the
PR polymer chain by hydrolysis, yielding a sus-
tained level of the CPT within the tumor cells.
In the present study, we conducted in vitro cell
culture studies to demonstrate the feasibility of this
Figure 1. Schematic illustration of the CPT–PR conju-
gates. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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CPT delivery system. The PR–CPT–LMWP conju-
gates were successfully synthesized and character-
ized. Furthermore, the controlled regulation of intra-
cellular uptake of these conjugates using heparin
and protamine was demonstrated.
EXPERIMENTAL PROCEDURES
Materials
Boc-L-tyrosine hydroxysuccinimide ester (BOC-Tyr-OSu)
was from purchased Fluka (Allentown, PA). Unless other-
wise stated, all chemicals including (S)-(þ)-CPT, (polyoxy-
ethylene glycol)bisamine (PEG-BA; average Mn: 3350 Da),
and a-CD were purchased from Sigma Chemical (St.
Louis, MO). All solvents were purchased from Aldrich




A schematic illustration of the synthesis of the LMWP–
PR–CPT conjugates is shown in Figure 2. Pseudo-PR was
first prepared according to the procedures of Harada and
Kamachi.19 In brief, 5 mL of solution containing 1 g PEG–
BA (3.0 3 104 mol) was added to a saturated solution of
a-CD (12 g, 1.2 3 102 mol), and the mixture was ultra-
sonically agitated for 1 h followed by stirring for 24 h at
room temperature. Precipitated pseudo-PR was collected
by centrifugation, dried under vacuum, and then stored at
room temperature for subsequent use (see Step 1 in Fig. 2).
To synthesize the PR polymer, Boc-Tyr-OSu (5 g, 1.3 3
102 mol in DMSO) was added to a DMSO solution con-
taining 12 g (4 3 104 mol) of the pseudo-PR, and the
reaction mixture was stirred at room temperature for 96 h.
The Tyr-capped PR polymer was precipitated by the addi-
tion of excess acetone, collected by centrifugation, washed
with ethanol and water, and then dried at room tempera-
ture (Step 2).
Figure 2. Schematic illustration of the synthesis of CPT–PR–LMWP conjugates.
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To prepare the PR–CPT conjugates, the Boc-Tyr-termi-
nated PR (1 g, 3.0 3 105 mol) was first activated with suc-
cinic anhydride (SA; 5 g, 5.0 3 102 mol in pyridine), and
the mixture was stirred at room temperature for 72 h. CPT
(350 mg, 1.0 3 103 mol) was then added to a toluene so-
lution (50 mL) containing 400 mg (1.0 3 105 mol) of the
activated PR carboxyethylester, and the solution was azeo-
troped for 2 h. The solvent was removed by vacuum, and
pyridine (50 mL) was added to dissolve the precipitate.
The solution was then cooled to 08C for 15 min, followed
by the addition of 2-chloro-1-methylpyridinium iodide
(530 mg, 2.0 3 103 mol) and 4-dimethylaminopyridine
(DMAP) (500 mg, 4.1 3 103 mol). The mixture was stirred
at room temperature for 96 h, and the product was pre-
cipitated by the addition of ether. Removal of the Boc
groups was carried out by following a well-established
procedure described by Han et al.20 The PR–CPT product
was collected by precipitation with ether, purified by
washing with 2-propanol, and then subjected to 1H NMR
(model no. DRX-500; Bruker Biospin, Billerica, CA) using
DMSO-d6 as the solvent for structural analysis (Step 3).
To synthesize the LMWP–PR–CPT conjugate, LMWP
was first prepared by digestion of native protamine with
thermolysin, according to previously established proce-
dures.14–17 The completely purified LMWP consists of 14
amino acids with a sequence of SRRRRRRGGRRRR.
Conjugation of LMWP to PR–CPT was carried out using
a modified procedure by Yang and coworkers17 (Step 4).
Fluorescence labeling
Twenty microliters of the Lissamine rhodamine B ethyl-
enediamine (Rho) dye, prepared in DMSO at a concentra-
tion of 10 mg/mL, was mixed with the drug conjugates
(PR–CPT or LMWP–PR–CPT) in labeling buffer (0.24M
methylimidazole, pH 9.0, 0.32M [1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide hydrochloride], EDC) at a final
CPT concentration of 2 lM. The mixture was reacted at
room temperature for 4 h, and fluorescence-labeled drug
conjugates were separated by size exclusion chromato-
graphy.
Determination of CPT content in the conjugates
To determine the CPT content in the PR–drug conju-
gates, *2 mg of the conjugates were placed in a volumet-
ric flask containing 20 mL of a 1:1 mixture of 50 mM
borate buffer (pH 9.5)/methanol solution. The flask was
shaken vigorously at 378C for 24 h, and the reaction was
quenched by the addition of concentrated H3PO4. The so-
lution was then analyzed using HPLC, with a C-18 Micro-
sorb-MV column (Rainin, Walnut Creek, CA) and an iso-
cratic mobile phase consisting of 25 % (v/v) acetonitrile
and 2% (w/v) triethylamine acetate. The lactone and car-
boxylate peaks in CPT were determined by the areas
under the absorbance curves at 254 nm at the 5- and 16-
min marks, respectively, from the HPLC chromatograms
and were then compared with the CPT standards.
Solubility determination
The solubility of free CPT and PR-bound CPT were
determined by adding the drug samples to vials contain-
ing 50 mM phosphate buffer (pH 7.4). The vials were incu-
bated with agitation, in a thermal bath at 378C for 24 h,
and insoluble materials were filtered with 0.45-lm-disc fil-
ters. The CPT content in the solutions of these samples
was then diluted with methanol and analyzed using
HPLC.
In vitro drug release studies
The release of CPT from the PR–drug conjugates by hy-
drolysis was evaluated at 378C in phosphate buffer (pH
7.4) containing 0.02% Tween 80. Approximately 1 mg of
the PR–CPT conjugates was suspended in 1 mL of PBS,
and then placed in a dialysis bag (molecular weight cut-
off: 3000 Da). The mixture was dialyzed against 30 mL
PBS at an agitation rate of 100 rpm, and 1 mL of the buffer
solution was collected at designated time intervals and an-
alyzed by HPLC. An equivalent volume of fresh buffer
was added to the release buffer after each sample with-
drawal.
In vitro cytotoxicity
CPT-induced cytotoxicity was assessed by a calorimetric
assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT). In brief, 1 3 105 A2780 human
ovarian cancer cells (ECACC, Salisbury, UK) were seeded
into 96-well plates. After 24 h incubation at 378C, the me-
dium was aspirated and 10 different concentrations of ster-
ile test substances (free CPT, PR–CPT, and LMWP–PR–
CPT) in fresh media were added. Control cells were
treated with an equivalent volume of Dulbecco’s phos-
phate buffered saline (DPBS). Cells were subsequently cul-
tured for 48 h, the medium was aspirated, and 100 lL of
fresh medium and 25 lL of 5 mg/mL MTT solution were
added to each well. The plates were incubated for 4 h at
378C and formazan crystals were dissolved by the addition
of DMSO. Finally, absorbance was measured at 570 nm.
Cell uptake assays
A2780 cells were plated on 4-well chamber slides at a
density of 1 3 104 cells/slide and incubated at 378C in a
humidified atmosphere of 5% CO2. After complete adhe-
sion, the cell medium was removed. Five test samples,
containing Rho-labeled CPT, including: (1) free CPT; (2)
PR–CPT; (3) LMWP–PR–CPT; (4) LMWP–PR–CPT þ hepa-
rin; and (5) LMWP–PR–CPT þ heparin þ protamine were
added to the cells at a final CPT concentration of 2 lM.
Following incubation for 2 h at 378C, cells were washed
with PBS, fixed with 1% paraformaldehyde, and visualized
using confocal laser scanning microscopy (Carl Zeiss, Got-
tingen, Germany).
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Flow cytometric analyses
A2780 cells were plated on 6-well plates at a density of
1 3 106 cells per well and incubated at 378C in humidified
atmosphere of 5% CO2 for 24 h. The cells were then
washed with PBS and incubated with the five previously
described test samples at a final CPT concentration of 2
lM for 2 h. Cells were washed with PBS to remove surface
bound drug conjugates and treated with trypsin–EDTA to
collect the cells. The cells were then fixed with 1% parafor-
maldehyde and washed with PBS. Analysis was conducted
on a FACScalibur flow cytometer (Beckton Dickinson, San
Jose, CA) equipped with a 488-nm air-cooled argon laser.
RESULTS
Synthesis and characterization of the
PR–CPT conjugates
As described previously, the PR–CPT conjugates
were synthesized by threading the a-CD residues
onto a PEG chain, blocking the two ends of the PEG
chain with bulky L-Tyr groups, activating the result-
ing PR polymer with SA, and then linking CPT on
the SA-activated groups via hydrolysable ester link-
ages. Figure 3 shows the NMR spectrum of the syn-
thesized PR–CPT conjugates, with peaks represent-
ing – 1H NMR (DMSO): d (ppm) ¼ 0.9 (t, C(18)H3 of
CPT), 1.9 (m, C(19)H2 of CPT), 2.3 (s, CH2 of CEE),
2.9 (m, CH2 of Tyr), 3.5(s, CH2 of PEG), 5.5, 5.6 (dd,
OH(2), OH(3) of CD), 8.3 (q, C(12) H1 of CPT). As
demonstrated by the related peaks for CPT, CD, Tyr,
and PEG, it was clear that the desired PR–CPT con-
jugates were successfully synthesized. The overall
yield of the PR–CPT conjugate was 56%, whereas
the average weight content of CPT in the conjugate
was *8.0% (w/w). The molecular weight of the PR–
CPT conjugate, as determined by the 1H NMR data,
was approximately 45 kDa. Based on these results,
each PR–CPT conjugate was calculated to possess
one PEG chain, 30 a-CD residues, and 10 CPT drug
molecules.
When compared to weight calculations of CPT,
the solubilities of free CPT and the PR–CPT conju-
gate were estimated to be 28.3 and 195.0 lg/mL,
respectively. This sevenfold increase in CPT solubil-
ity by the PR–CPT conjugate was apparently influ-
enced by both the hydrophilic nature of the polymer
constituents (PEG and CDs) as well as the presence
of abundant COOH groups resulting from activa-
tion of the OH groups on the CD residues by SA.
The release of CPT by hydrolysis from the PR–
CPT conjugates was also examined in vitro under
physiological conditions (Fig. 4). Within first 5 h of
incubation, a burst release of CPT was observed,
with less than 20% of total CPT bonds hydrolyzed.
After the initial effect, a nearly linear and sustained
release profile of the drug was seen over an
extended period. By day 7, more than 75% of CPT
on the polymer–drug conjugates had been released
by hydrolysis.
In vitro cytotoxicity studies
Cytotoxicity of the PR–drug conjugates were
examined in vitro against the A2780 human ovarian
cancer cell line using the MTT method. The ID50 val-
ues for free CPT, PR–CPT, and LMWP–PR–CPT, as
determined from the MTT cytotoxicity assay (Fig. 5),
were 0.006, 1.41, and 0.13 lM, respectively. While
the LMWP–PR–CPT conjugate was about 20-fold
less potent in killing cancer cells than free CPT, it
nevertheless yielded a 10-fold increase in the cyto-
Figure 3. NMR spectrum of the synthesized CPT–PR con-
jugates.
Figure 4. CPT release from CPT–PR conjugate in PBS
(pH 7.4).
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toxic effect over that of the conjugate without attach-
ment of the cell-penetrating LMWP peptide.
LMWP-mediated intracellular delivery of CPT and
regulation by heparin and protamine
CPT exhibits its own blue fluorescence with excita-
tion and emission wavelengths of 370 and 435 nm,
respectively. To monitor LMWP-mediated intracellu-
lar delivery of the conjugates, the PR chain was la-
beled with Rho (excitation at 570 nm and emission
at 590 nm) on the carboxylic acid groups. When free
CPT was added, the small and hydrophobic CPT
molecules were able to diffuse into the cells with
ease following 2 h of incubation, as reflected by the
high intensity of blue fluorescence within the
exposed cells (Fig. 6.1). On the other hand, the PR–
CPT conjugates were not taken up by the carcinoma
cells (Fig. 6.2), primarily due to the macromolecular
structure of the PR polymer. Conversely, the
LMWP–PR–CPT conjugates were able to internalize
into the cells, as the blue CPT-derived fluorescence
and red fluorescence from Rho-labeled PR were
superimposed inside cells including colocalization
(Fig. 6.3). These results indicated that the cell-perme-
able LMWP was able to carry the attached PR–CPT
conjugates across cell membranes. When heparin
was added, this LMWP–induced cell transduction
function was markedly abolished (Fig. 6.4), likely
due to the electrostatic interactions between the posi-
tively-charged LWMP and negatively-charged hepa-
rin molecules. Yet, when protamine was added to
the mixture, the heparin-induced inhibition was
nearly completely reversed (Fig. 6.5), as demon-
strated by recovery of CPT (blue) and the PR chains
(red) of fluorescence colocalization within the cells.
Consistent with these findings, flow cytometric anal-
ysis indicated that LMWP was able to ferry the cell-
impermeable PR–CPT conjugates into the carcinoma
cells (Fig. 7). Similarly, this LMWP-mediated intra-
cellular uptake was inhibited by the addition of hep-
arin but was recovered by the addition of protamine
to the heparin-masked LMWP–PR–CPT conjugates.
DISCUSSION
Most potential antitumor agents including CPT
face a major hurdle in their clinical applications, due
to a lack of target selectivity for their therapeutic
actions. While drug action against tumor cells would
result in therapeutic efficacy, actions on normal tis-
sues would consequently lead to toxic side effects.
To counter this problem, the use of polymer-based
carriers for delivery of such small hydrophobic
agents have been extensively explored and actively
pursued; simply because these nanocarrier systems
would be able to accumulate within tumors based
on the EPR-mediated passive targeting. Among the
various polymer carrier systems, the unique PR
supramolecular assembly offers an appealing plat-
form for drug delivery due to several key advan-
tages. First, the two primary building blocks of PR,
a-CD, and PEG are both widely used throughout the
pharmaceutical industry and are considered safe and
relatively nontoxic. In addition, the large number of
hydroxyl groups on the a-CD residues of PR can be
easily modified and function as multivalent drug
carriers and also used to improve the physicochemi-
cal properties of the attached drug molecules, such
as solubility and stability. Furthermore, both the size
and molecular weight of the PR carrier can be read-
ily regulated, either by altering the chain length of
PEG or by changing the molar ratio between a-CD
and PEG during the threading process, to produce
the most desirable platform in avoiding renal filtra-
tion and reticuloendothelial system clearance. Simi-
larly, the ability to modify the size of the PR carrier
also facilitates the EPR-induced passive tumor tar-
geting. According to our results, the synthesized PR
possessed a molecular weight of 40–45 kDa, as deter-
mined NMR and confirmed by gel filtration chroma-
tography by utilizing poly (2-vinylpyridine) and cer-
tain standard proteins as molecular weight markers.
Using 1H NMR analysis, the number of a-CD mole-
cules inserted onto the PEG chain and the SA-acti-
vated carboxyethylester groups were estimated to be
30 and 100, respectively. The average molar ratio of
ethylene oxide/CD was 2.5, which was in reasonable
agreement with the theoretical value of 2.0–2.2 sug-
gested by other investigators.8,19 Nevertheless, CPT
Figure 5. Cytotoxicity of CPT and CPT–polymer conju-
gates. Free CPT (^), CPT–PR (n), and CPT–PR–LMWP
(~) conjugates against A2780 human ovarian cancer cells
in log-phase culture. Values represented as mean 6 SD.
Each experiment was performed in triplicate.
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Figure 6. Cellular localization of Rho-labeled LMWP–drug conjugates in A2780 human ovarian carcinoma cells. Free
CPT, Rho-labeled CPT–PR, Rho-labeled CPT–PR–LMWP, Rho-labeled CPT–PR–LMWP and heparin mixture, and Rho-la-
beled CPT–PR–LMWP, heparin, and protamine mixture were overlaid onto cultured A2780 cells in the presence of 10%
FBS. Cellular localization was monitored by confocal microscopy. (1) Free CPT; (2) Rho-labeled CPT–PR; (3) Rho-labeled
CPT–PR–LMWP; (4) Rho-labeled CPT–PR–LMWP and heparin mixture; (5) Rho-labeled CPT–PR–LMWP, heparin, and
protamine mixture. (A) 430 nm (blue) detection; (B) 560 nm (red) detection; (C) overlaid (A þ B). [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
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loading on the PR–CPT conjugates was only *8%
(w/w), suggesting that only *10% of the activated
carboxyethylester binding sites on the PR chains
were occupied by CPT molecules. This phenomenon
may be accounted for by the steric hindrance that is
imparted by the rather large CPT structure which
could block additional drug loading. Other research-
ers have demonstrated that by introducing spacer
arms even as small as glycine residues between the
poly(glutamic acid) chain and the attached drug,21
drug loading can be significantly increased in the
PR-based conjugates. Future investigation is there-
fore aimed towards further improvement of the
drug loading of the PR-based drug carrier.
As expected, conjugation of CPT to PR resulted in
certain polymer-induced beneficial effects, such as
improved solubility and stability of the drug. Results
showed that the hydrophilic character of PR
improved the overall solubility of the hydrophobic
CPT nearly sevenfold; from the initial 29–195 g/mL.
In addition, linking of CPT to the PR polymer via
the OH group at the C(20) position of CPT also pro-
tects the lactone ring of the drug molecule from hy-
drolysis, thereby preserving the therapeutic activity
of the drug. It has been demonstrated by other
investigators that when CPT is modified in a similar
fashion by attaching the drug molecule to a poly
(glutamic acid) polymer via the C(20)-OH group, it
has displayed significantly enhanced stability and
therapeutic efficacy in vivo.21
From in vitro release studies, a burst release (*20%)
of CPT from the PR–drug conjugates was observed,
followed by a nearly linear, sustained release of the
drug over the period of more than 7 days. This release
rate, which was governed primarily by the rate of hy-
drolysis of the ester bond between CPT and PR, could
be readily manipulated by adopting different chemical
linkages. It still remains unclear as to which factors
may have contributed to the burst release of CPT at
the initial stage, although nonspecific adsorption of
free CPT molecules on the conjugates during their syn-
thesis as well as unanticipated hydrolysis of CPT from
the conjugates during storage may offer some specula-
tions into this observation. Based on comparison of
the molecular weight of the CPT-linked a-CD mono-
mers (theoretical maximum: 3700 Da, practical aver-
age: 1430 Da) to the cut-off range of the dialysis tubing
employed in the release studies (3.0 kDa), it seems
likely that the released CPT was not the free form of
drug, but rather the CPT-containing a-CD monomers
resulting from dethreading of the PR–CPT conjugates.
Identification of the presence of a-CD monomers in
the release medium by NMR analysis will be con-
ducted in future experiments to verify this possibility.
In vitro cytotoxicity results indicated that the ID50
of the PR–CPT conjugates in A2780 cells was more
than 200-fold higher than that for free CPT (1.41 lM
versus 0.006 lM). This finding was expected, as the
small and hydrophobic nature of CPT allows for cel-
lular uptake to readily occur by passive diffusion. In
contrast the membrane-impermeable, macromolecu-
lar PR–CPT conjugates could not be internalized by
the cells to induce the cytotoxic effects of CPT. Inter-
estingly but as anticipated, the LMWP–PR–CPT con-
jugates exhibited a 10-fold reduction in the ID50
value when compared to the PR–CPT conjugates
without LMWP (0.13M versus 1.41M). This increased
cytotoxicity occurred probably because, even though
the LMWP–PR–CPT conjugates were water soluble
macromolecular structures, they were nevertheless
internalized by the cells due to the demonstrated
transmembrane activity of LMWP.17
As previously discussed, carrier-based delivery
systems of small drugs with a sustained release fea-
ture (e.g., liposomal delivery systems) may achieve
tumor accumulation via the EPR effect, followed by
local release of drug at the tumor interstitium for the
extended antitumor effect. However, the build-up of
the interstitial concentration of the released drugs
may cause the drugs to diffuse outside the tumor
and potentially create the cytotoxic effects to the nor-
mal tissues surrounding the tumor. To overcome
this obstacle, the enhanced intracellular uptake of
the carrier at the tumor may be needed. To this
regard, we have developed a novel strategy by inte-
grating prodrug features into the LMWP-mediated
intracellular drug delivery. During incubation of the
LMWP–PR–CPT conjugates with tumor cells, an in
vitro process that can partially mimic tumor target-
ing by the EPR effect, heparin was used to electro-
statically mask the transmembrane activity of LMWP
on the conjugates to yield the prodrug feature. Our
Figure 7. Flow cytometric analysis of cell uptake by Rho-
labeled LMWP PR conjugate, Rho-labeled PR–LMWP and
heparin mixture, Rho-labeled PR–LMWP, heparin and
protamine mixture. Blank (blue), PR (green), Rho-labeled
LMWP–PR conjugate (orange), Rho-labeled PR–LMWP
and heparin mixture (yellow), and Rho-labeled PR–
LMWP, heparin and protamine mixture (purple). [Color
figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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results showed that the addition of heparin was able
to inhibit internalization of the LMWP–PR–CPT con-
jugates, although it appears that some translocation
did occur. One hypothesis was that an insufficient
amount of heparin was added to the LMWP–PR–
CPT conjugates, rendering its inhibition on LMWP
incomplete. Another possible explanation may be
competition of cell surface heparin sulfate moieties
with the administered heparin inhibitor. It has previ-
ously been demonstrated that negatively charged
cell surface proteoglycans are required for PTD
transduction. However, there exact mechanisms
remain unconfirmed. Nevertheless, this prodrug
function mediated by heparin to prevent internaliza-
tion can inhibit the CPT-induced cytotoxic effects,
and was clearly demonstrated by both confocal and
flow cytometry results. Therefore, following hypo-
thetical tumor accumulation of the macromolecular
prodrug conjugates by EPR targeting, the LMWP-
mediated cell internalization can be successfully
restored by the addition of protamine to the hepa-
rin-inhibited drug conjugates. With this approach,
this novel PR-based drug delivery system can be
passively targeted to the tumor interstitium, but also
allows for internalization of the complete polymer–
drug complex as opposed to requiring hydrolysis
and subsequent drug diffusion into tumor cells.
In conclusion, the in vitro feasibility of this novel
PR-based CPT delivery system was demonstrated.
Extensive animal studies are currently in progress in
our laboratory, with the aims at further validating
this novel CPT delivery strategy. It should be
pointed out that should in vivo tumor targeting and
therapy prove successful, this PR-based strategy
could evolve as a generic system for the delivery of
various small antitumor agents that possess poor sol-
ubility and reaction selectivity.
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